This is a UIVII application to support the infrastructure of the original Nurses' Health Study (NHS). The NHS began in 1976 with 121,700 women, and has accumulated data from 19 questionnaires over 37 years; follow-up remains about 90 percent. The wealth of behavioral data combined with multiple bio-specimen collections, including blood, toenails, urine, buccal cells and tumor tissues beginning in 1.983 from a substantial proportion of women, provide an unparalleled resource in studying cancer prevention, etiology, and survival. Sustained follow-up of the NHS through repeated questionnaire mailings and continued identification of cancer incidence and mortality will permit critical new research. With the cohort's maturation (women are now 66+ years, at peak ages for cancer incidence), we propose to add emphasis to two overarching themes. First, we propose to expand the infrastructure for cancer survival research, including both the duration and quality of life in cancer patients. The many years of characterization of cancer patients before and after diagnosis, will allow us to distinguish between causes and consequences of cancer and its treatment. Second, we propose to improve our infrastructure to support a systems biology approach to our research, integrating questionnaire data with biomarkers in DNA, blood, tumor tissue, and other bio specimens; such research simultaneously integrating multiple systems, including behavior, genomics, transcriptomics, metabolomics, etc., may illuminate new mechanisms underlying cancer. Our large and growing number of incident cancer cases, and the unique combination of questionnaires and bio specimens, are a necessity for such integrative research. Specifically, our Aims include new collection of quality of life data, new (collection of tumor tissue (resulting in tissue collections, across 17 cancer sites), improved dat management/statistical support for big data analyses, and enhanced infrastructure for data sharing (the NHS resource is already extensively utilized - we have provided access to >75 external investigators in the past 5-6 years and 27 NCI cancer consortia). The NHS structure combines the long experience of senior leaders with support of several developing leaders; this combination is purposeful, to maintain leadership to sustain the cohort's future. In conclusion, NHS is well-positioned to continue cutting-edge research to reduce cancer morbidity and mortality. With the previous investment from NIH and investigators, the incremental costs of continuing this cohort are modest in relation to the uniquely valuable findings that will emerge in the coming 5 years.

Public Health Relevance

This UMI application is to extend follow-up of the original Nurses' Health Study, with extensive data on health, and lifestyle, integrated with biologic data (e.g., genomics, plasma biomarkers, tumor tissue, etc.), enabling novel research on cancer etiology, prevention and survival. No other cohort of comparable size includes such long follow-up with repeated behavioral measures, and bio specimens from 82,000 women. This enables studies of the time frame for causal and preventive factors for cancer etiology and survival.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1CA186107-05
Application #
9521371
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Ellison, Gary L
Project Start
2014-07-22
Project End
2019-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
Gupta, Shruti; Curhan, Sharon G; Curhan, Gary C (2018) Biomarkers of Systemic Inflammation and Risk of Incident Hearing Loss. Ear Hear :
Kim, Iris Y; O'Reilly, Éilis J; Hughes, Katherine C et al. (2018) Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Mov Disord 33:414-420
Song, Mingyang; Wu, Kana; Meyerhardt, Jeffrey A et al. (2018) Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol 4:71-79
Wang, Tiange; Heianza, Yoriko; Sun, Dianjianyi et al. (2018) Improving adherence to healthy dietary patterns, genetic risk, and long term weight gain: gene-diet interaction analysis in two prospective cohort studies. BMJ 360:j5644
Merritt, Melissa A; Rice, Megan S; Barnard, Mollie E et al. (2018) Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study. Lancet Oncol 19:1107-1116
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Jung, Seungyoun; Allen, Naomi; Arslan, Alan A et al. (2018) Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts. Int J Cancer 142:262-270
Bertrand, Kimberly A; Eliassen, A Heather; Hankinson, Susan E et al. (2018) Circulating Hormones and Mammographic Density in Premenopausal Women. Horm Cancer 9:117-127
Hamada, Tsuyoshi; Zhang, Xuehong; Mima, Kosuke et al. (2018) Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. Cancer Immunol Res 6:1327-1336
Sparks, Jeffrey A; Lin, Tzu-Chieh; Camargo Jr, Carlos A et al. (2018) Rheumatoid arthritis and risk of chronic obstructive pulmonary disease or asthma among women: A marginal structural model analysis in the Nurses' Health Study. Semin Arthritis Rheum 47:639-648

Showing the most recent 10 out of 489 publications